Detection of β‐Amyloid by Sialic Acid Coated Bovine Serum Albumin Magnetic Nanoparticles in a Mouse Model of Alzheimer's Disease

Nasr, Seyedmehdi Hossaini; Kouyoumdjian, Hovig; Mallett, Christiane L.; Ramadan, Sherif; Zhu, David C.; Shapiro, Erik M.; Huang, Xuefei

doi:10.1002/smll.201701828

Cited by 43 publications

(22 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the accumulation and/or the formation of Aβ plaques are some of the most prominent pathological hallmarks of AD, designing NPs- contrast agents that can selectively bind to Aβ, are br capable platforms for aiding the timely detection of AD. In this respect, Nasr et al synthesized Sialic acid-coated bovine serum albumin (BSA) magnetic NPs which bind to Aβ deposits, with high selectivity [99]. The NP-BSAx-Sia could penetrate the BBB and allow for the detection of Aβ plaques using magnetic resonance imaging (MRI) in an AD mouse model without requiring of mannitol to open the BBB.…”

Section: Current Research Advances In Nanoparticle-based Treatmentmentioning

confidence: 99%

Nanomaterials for Drug Delivery to the Central Nervous System

et al. 2019

View full text Add to dashboard Cite

The intricate microstructure of the blood-brain barrier (BBB) is responsible for the accurate intrinsic regulation of the central nervous system (CNS), in terms of neuronal pathophysiological phenomena. Any disruption to the BBB can be associated with genetic defects triggering or with local antigenic invasion (either neurotoxic blood-derived metabolites and residues or microbial pathogens). Such events can be further related to systemic inflammatory or immune disorders, which can subsequently initiate several neurodegenerative pathways. Any degenerative process related to the CNS results in progressive and yet incurable impairment of neuronal cells. Since these particular neurons are mostly scanty or incapable of self-repair and regeneration processes, there is tremendous worldwide interest in novel therapeutic strategies for such specific conditions. Alzheimer’s and Parkinson’s diseases (AD and PD, respectively) are conditions found worldwide, being considered the most rampant degenerative pathologies related to CNS. The current therapy of these conditions, including both clinical and experimental approaches, mainly enables symptom management and subsidiary neuronal protection and even less disease regression. Still, a thorough understanding of the BBB pathophysiology and an accurate molecular and sub-molecular management of AD and PD will provide beneficial support for more specific and selective therapy. Since nanotechnology-derived materials and devices proved attractive and efficient platforms for modern biomedicine (including detection, imaging, diagnosis, medication, restoration and regeneration), a particular approach for AD and PD management relies on nanoparticle-based therapy. In this paper we will discuss relevant aspects related to the BBB and its impact on drug-based treatment and emphasize that nanoparticles are suitable and versatile candidates for the development of novel and performance-enhanced nanopharmaceuticals for neurodegenerative conditions therapy.

show abstract

Section: Current Research Advances In Nanoparticle-based Treatmentmentioning

confidence: 99%

Nanomaterials for Drug Delivery to the Central Nervous System

et al. 2019

View full text Add to dashboard Cite

show abstract

“…[ 16 , 17 , 18 , 19 ] Different biological/ synthetic polymers and colloidal nanoparticles with multiple SA units have demonstrated their surface‐protecting/masking properties, resulting in prolonged circulation times and enhanced pharmacokinetic parameters. [ 20 , 21 , 22 , 23 ] Based on these advantageous properties, in this paper we describe a combined biohybrid strategy to tackle the issues that normally prevent an efficient photodynamic response of Pc against tumoral diseases. On one hand, decorating the ZnPc macrocycle with SA‐containing dendritic arms to ensure water‐solubility, biocompatibility and cell internalization.…”

Section: Introductionmentioning

confidence: 99%

Tuning the Nanoaggregates of Sialylated Biohybrid Photosensitizers for Intracellular Activation of the Photodynamic Response

Almeida-Marrero

Mascaraque

Vicente-Arana

et al. 2021

Chemistry A European J

View full text Add to dashboard Cite

In the endeavor of extending the clinical use of photodynamic therapy (PDT) for the treatment of superficial cancers and other neoplastic diseases, deeper knowledge and control of the subcellular processes that determine the response of photosensitizers (PS) are needed. Recent strategies in this direction involve the use of activatable and nanostructured PS. Here, both capacities have been tuned in two dendritic zinc(II) phthalocyanine (ZnPc) derivatives, either asymmetrically or symmetrically substituted with 3 and 12 copies of the carbohydrate sialic acid (SA), respectively. Interestingly, the amphiphilic ZnPc‐SA biohybrid (1) self‐assembles into well‐defined nanoaggregates in aqueous solution, facilitating cellular internalization and transport whereas the PS remains inactive. Within the cells, these nanostructured hybrids localize in the lysosomes, as usually happens for anionic and hydrophilic aggregated PS. Yet, in contrast to most of them (e. g., compound 2), hybrid 1 recovers the capacity for photoinduced ROS generation within the target organelles due to its amphiphilic character; this allows disruption of aggregation when the compound is inserted into the lysosomal membrane, with the concomitant highly efficient PDT response.

show abstract

“…Finally, we evaluated and discussed the potential of PDLC NPs for future clinical applications. Drug delivery to the brain is hindered by a number of obstacles and the foremost is crossing the blood–brain barrier (BBB) . We first studied the intracellular uptake behavior of PDLC NPs toward PC12 cells.…”

Section: Resultsmentioning

confidence: 99%

Engineering Versatile Nanoparticles for Near‐Infrared Light‐Tunable Drug Release and Photothermal Degradation of Amyloid β

Lai

Zhu

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Nanomedicines that inhibit/disassemble amyloid β (Aβ) aggregates in Alzheimer's disease (AD) are highly desirable yet remain challenging. Therapeutic efficacy and systemic delivery of reported molecules and nanoparticles (NPs) are hampered by various challenges, including low biocompatibility, off‐target toxicity, and lack of specificity. Herein, a versatile NP is designed by integrating high Aβ‐binding affinity, stimuli‐responsive drug release, and photothermal degradation properties for efficient disassembly of Aβ. Near‐infrared (NIR)‐absorbing conjugated polymer PDPP3T‐O14 serves as a photothermal core while thermal‐responsive polymer 1,2‐dipalmitoyl‐sn‐glycero‐3‐phosphocholine at the outer layer as the NIR‐stimuli gatekeeper. Curcumin, an inhibitor of Aβ aggregation, is loaded into the NP with high encapsulation efficiency. The 5‐mer β‐sheet breaker peptides LPFFD (Leu‐Pro‐Phe‐Phe‐Asp) having high binding affinity toward Aβ are further anchored onto the surface of polyethylene glycol‐lipid shell for active Aβ‐targeting. The resultant NPs exhibit good Aβ‐targeting ability and obvious photothermal dissociation effect together with Aβ aggregation‐dependent fluorescence detection capability. Upon NIR laser irradiation, entrapped curcumin can be effectively released from the unconsolidated NPs to enhance the anti‐amyloid activity. In vitro studies demonstrate that the NPs dramatically lower Aβ‐induced cytotoxicity of PC12 cells, and therefore show great potential for the application in AD treatment.

show abstract

Detection of β‐Amyloid by Sialic Acid Coated Bovine Serum Albumin Magnetic Nanoparticles in a Mouse Model of Alzheimer's Disease

Cited by 43 publications

References 76 publications

Nanomaterials for Drug Delivery to the Central Nervous System

Nanomaterials for Drug Delivery to the Central Nervous System

Tuning the Nanoaggregates of Sialylated Biohybrid Photosensitizers for Intracellular Activation of the Photodynamic Response

Engineering Versatile Nanoparticles for Near‐Infrared Light‐Tunable Drug Release and Photothermal Degradation of Amyloid β

Contact Info

Product

Resources

About